Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
March 29, 2016 09:25 ET
|
Summit Therapeutics plc
Data to be Presented at 26th ECCMID Conference, 11 April 2016 OXFORD, United Kingdom, March 29, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and...
Assembly Biosciences to Webcast Upcoming Investor Conferences
February 19, 2016 07:30 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut...
Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract
January 27, 2016 07:30 ET
|
Assembly Biosciences, Inc.
PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B...
Assembly Biosciences to Present at Jefferies Microbiome Summit
December 16, 2015 07:30 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
C. difficile Infection Increases Hospital Costs by 40 Percent Per Case, Study Finds
December 10, 2015 09:27 ET
|
Premier, Inc.
Patients with C. diff stay in hospital 55 percent longer and are 77 percent more likely to be readmitted CHARLOTTE, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Clostridium difficile (C. diff),...
Clinical Study Shows Assembly Biosciences' Oral Gemicel™ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
December 09, 2015 07:00 ET
|
Assembly Biosciences, Inc.
—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress
August 27, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
August 24, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
June 11, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...